Vaxcyte (PCVX) Assets Average (2020 - 2026)

Vaxcyte (PCVX) has 7 years of Assets Average data on file, last reported at $3.2 billion in Q1 2026.

• On a quarterly basis, Assets Average fell 7.81% year-over-year to $3.2 billion in Q1 2026; TTM through Mar 2026 was $3.2 billion, a 7.81% decrease from a year earlier, with the FY2025 full-year figure at $3.3 billion, up 32.42% from the prior year.
• Assets Average for Q1 2026 stood at $3.2 billion, up from $3.1 billion in the prior quarter.
• Over the last five years, Assets Average for PCVX reached as high as $3.5 billion in Q4 2024 and fell as low as $363.5 million in Q1 2022.
• Historically, Assets Average has averaged $2.0 billion across 5 years, with a median of $1.7 billion in 2024.
• Across the five-year window, Assets Average jumped 264.08% in 2023 and fell 12.68% in 2025, its largest moves.
• Year by year, Assets Average stood at $709.1 million in 2022, then jumped by 104.76% to $1.5 billion in 2023, then surged by 143.5% to $3.5 billion in 2024, then decreased by 12.68% to $3.1 billion in 2025, then rose by 2.86% to $3.2 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $3.2 billion in Q1 2026, $3.1 billion in Q4 2025, and $3.2 billion in Q3 2025.